Research project
Evaluation of patient preferences for and cost effectiveness of community intravenous antibiotic services (CIVAS)
- Start date: -
- End date: -
- Partners and collaborators: Funding: National Institute for Health Research (NIHR) Health Services and Delivery Research (HS&DR)
- Co-investigators: Czoski-Murray (ÂÌñ»»ÆÞ Institute of Health Sciences), Meads (ÂÌñ»»ÆÞ Institute of Health Sciences), Hess (Institute of Transport Studies), Vargas-Palacios (ÂÌñ»»ÆÞ Institute of Health Sciences), Mitchell (ÂÌñ»»ÆÞ Institute of Health Sciences), Wright (ÂÌñ»»ÆÞ Institute of Health Sciences), Hulme (ÂÌñ»»ÆÞ Institute of Health Sciences), Raynor (School of Healthcare), McLintock (ÂÌñ»»ÆÞ Institute of Health Sciences), Twiddy (ÂÌñ»»ÆÞ Institute of Health Sciences)
- External co-investigators: Minton (ÂÌñ»»ÆÞ Teaching Hospitals NHS Acute Trust), Gregson (ÂÌñ»»ÆÞ Community Healthcare Trust), Stanley (Bradford Teaching Hospitals NHS Foundation Trust), Vincent (ÂÌñ»»ÆÞ Teaching Hospitals NHS Acute Trust)
Description
Aims
1. Establish the types of Outpatient Parenteral Antimicrobial Therapy (OPAT) services available in England and identify barriers to the use of each service type
2. Evaluate patients’ preferences for different service models of delivering OPAT
3. Assess the cost-effectiveness of different service models of delivering OPAT
Method
Using a mixed methods approach the study included 7 centres providing OPAT and covering 4 main service models: hospital attendance, specialised nurse visiting at home, general nurse visiting at home, self or carer administration. The methods were:
- Systematic review
- Survey of health professionals
- Qualitative study of patient perceptions
- Quantitative analysis of patient preferences
- Cost effectiveness study
- Expert panel
Background
Intravenous (IV) antibiotic treatment was developed for patients in hospital, but for some years it has been accepted practice in most developed countries to provide this for patients living in the community, known as Outpatient Parenteral Antimicrobial Therapy (OPAT). There is evidence that it is safe, generally welcomed by patients and that there are opportunities for improved cost-effectiveness and increasing hospital capacity. However, OPAT has been slow to become established in the UK, with service provision being limited to clinical providers with effective, enthusiastic champions delivering a variety of different models of care. There is limited evidence available for NHS health care providers and commissioners to facilitate service development.
People
Minton, ÂÌñ»»ÆÞ Teaching Hospitals NHS Acute Trust
Czoski-Murray, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Meads, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Hess, Institute of Transport Studies, ÂÌñ»»ÆÞ
Vargas-Palacios, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Mitchell, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Wright, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Hulme, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Raynor, School of Healthcare, ÂÌñ»»ÆÞ
Gregson, ÂÌñ»»ÆÞ Community Healthcare Trust
Stanley, Bradford Teaching Hospitals NHS Foundation Trust
McLintock, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Vincent, ÂÌñ»»ÆÞ Teaching Hospitals NHS Acute Trust
Twiddy, ÂÌñ»»ÆÞ Institute of Health Sciences, ÂÌñ»»ÆÞ
Funding body
NIHR HS & DR
Contact
Prof DK Theo Raynor d.k.raynor@leeds.ac.uk